MovDisordV3, PascalFrancis, Corpus, bibRecord, 001A92

Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease : A randomized controlled trial

Identifieur interne : 001A92 ( PascalFrancis/Corpus ); précédent : 001A91; suivant : 001A93

Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease : A randomized controlled trial

Auteurs : Yoshihiro Sato ; Jun Iwamoto ; Tomohiro Kanoko ; Kei Satoh

Source :

Movement disorders [ 0885-3185 ] ; 2006.

RBID : Pascal:06-0393852

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Fracture, Parkinson maladie, Hypercalcémie, Acide alendronique, Ergocalciférol, Prévention, Hanche, Vitamine D, Calcium, Elément minéral.

English descriptors

KwdEn :
- Alendronic acid, Calcium, Ergocalciferol, Fracture, Hip, Hypercalcemia, Inorganic element, Nervous system diseases, Parkinson disease, Prevention, Vitamin D.

Abstract

Incidence of a fracture, particularly in the hip joint, is high in elderly women with Parkinson's disease (PD), and this is due to the immobilization-induced bone resorption and vitamin D deficiency with reduced bone mineral density (BMD). The objective of this study was to address the possibility that treatment with alendronate and vitamin D2 may reduce the incidence of hip fractures in elderly women with PD. PD patients were randomly assigned to daily treatment with 5 mg alendronate (n = 144) or a placebo combined with 1,000 IU of vitamin D2 (n = 144) and followed for 2 years. Incidence of hip fractures in the two patient groups during the 2-year follow-up period was studied. At baseline, both groups of patients had low BMD with high levels of serum-ionized calcium and urinary deoxypyridinoline (D-Pyr). Hip fractures occurred in 14 patients in the placebo group and 4 in the alendronate group. The relative risk for hip fractures in the alendronate group as compared with the placebo group was 0.29 (95% CI, 0.10-0.85). The number of hip fracture per 1,000 patient-years was 14 and 49 for the alendronate and placebo groups, respectively. In the alendronate group, serum calcium and urinary D-Pyr levels decreased significantly during the follow-up period, while the levels in the placebo group were increased. BMD increased by 3.1% in the alendronate group and decreased by 2.8% in the placebo group (P < 0.01). Treatment with alendronate and vitamin D2 increases BMD in elderly women with PD and leads to the prevention of hip fractures.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 21`
A06				`@2 7`
A08	`01`	`1`	`ENG`	`@1 Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease : A randomized controlled trial`
A11	`01`	`1`		`@1 SATO (Yoshihiro)`
A11	`02`	`1`		`@1 IWAMOTO (Jun)`
A11	`03`	`1`		`@1 KANOKO (Tomohiro)`
A11	`04`	`1`		`@1 SATOH (Kei)`
A14	`01`			`@1 Department of Neurology, Mitate Hospital @2 Tagawa @3 JPN @Z 1 aut.`
A14	`02`			`@1 Department of Sports Medicine, Keio University School of Medicine @2 Tokyo @3 JPN @Z 2 aut.`
A14	`03`			`@1 Department of Rehabilitation Medicine, Institute of Brain Science, Hirosaki University School of Medicine @2 Hirosaki @3 JPN @Z 3 aut.`
A14	`04`			`@1 Department of Vascular Biology, Institute of Brain Science, Hirosaki University School of Medicine @2 Hirosaki @3 JPN @Z 4 aut.`
A20				`@1 924-929`
A21				`@1 2006`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000133412770070`
A44				`@0 0000 @1 © 2006 INIST-CNRS. All rights reserved.`
A45				`@0 23 ref.`
A47	`01`	`1`		`@0 06-0393852`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Incidence of a fracture, particularly in the hip joint, is high in elderly women with Parkinson's disease (PD), and this is due to the immobilization-induced bone resorption and vitamin D deficiency with reduced bone mineral density (BMD). The objective of this study was to address the possibility that treatment with alendronate and vitamin D2 may reduce the incidence of hip fractures in elderly women with PD. PD patients were randomly assigned to daily treatment with 5 mg alendronate (n = 144) or a placebo combined with 1,000 IU of vitamin D2 (n = 144) and followed for 2 years. Incidence of hip fractures in the two patient groups during the 2-year follow-up period was studied. At baseline, both groups of patients had low BMD with high levels of serum-ionized calcium and urinary deoxypyridinoline (D-Pyr). Hip fractures occurred in 14 patients in the placebo group and 4 in the alendronate group. The relative risk for hip fractures in the alendronate group as compared with the placebo group was 0.29 (95% CI, 0.10-0.85). The number of hip fracture per 1,000 patient-years was 14 and 49 for the alendronate and placebo groups, respectively. In the alendronate group, serum calcium and urinary D-Pyr levels decreased significantly during the follow-up period, while the levels in the placebo group were increased. BMD increased by 3.1% in the alendronate group and decreased by 2.8% in the placebo group (P < 0.01). Treatment with alendronate and vitamin D2 increases BMD in elderly women with PD and leads to the prevention of hip fractures.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C02	`03`	`X`		`@0 002B17A03`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Fracture @5 02`
C03	`02`	`X`	`ENG`	`@0 Fracture @5 02`
C03	`02`	`X`	`SPA`	`@0 Fractura @5 02`
C03	`03`	`X`	`FRE`	`@0 Parkinson maladie @5 03`
C03	`03`	`X`	`ENG`	`@0 Parkinson disease @5 03`
C03	`03`	`X`	`SPA`	`@0 Parkinson enfermedad @5 03`
C03	`04`	`X`	`FRE`	`@0 Hypercalcémie @5 04`
C03	`04`	`X`	`ENG`	`@0 Hypercalcemia @5 04`
C03	`04`	`X`	`SPA`	`@0 Hipercalcemia @5 04`
C03	`05`	`X`	`FRE`	`@0 Acide alendronique @2 NK @2 FR @5 09`
C03	`05`	`X`	`ENG`	`@0 Alendronic acid @2 NK @2 FR @5 09`
C03	`05`	`X`	`SPA`	`@0 Acido alendrónico @2 NK @2 FR @5 09`
C03	`06`	`X`	`FRE`	`@0 Ergocalciférol @2 NK @2 FR @5 10`
C03	`06`	`X`	`ENG`	`@0 Ergocalciferol @2 NK @2 FR @5 10`
C03	`06`	`X`	`SPA`	`@0 Ergocalciferol @2 NK @2 FR @5 10`
C03	`07`	`X`	`FRE`	`@0 Prévention @5 11`
C03	`07`	`X`	`ENG`	`@0 Prevention @5 11`
C03	`07`	`X`	`SPA`	`@0 Prevención @5 11`
C03	`08`	`X`	`FRE`	`@0 Hanche @5 12`
C03	`08`	`X`	`ENG`	`@0 Hip @5 12`
C03	`08`	`X`	`SPA`	`@0 Cadera @5 12`
C03	`09`	`X`	`FRE`	`@0 Vitamine D @2 NK @2 FR @5 13`
C03	`09`	`X`	`ENG`	`@0 Vitamin D @2 NK @2 FR @5 13`
C03	`09`	`X`	`SPA`	`@0 Vitamina D @2 NK @2 FR @5 13`
C03	`10`	`X`	`FRE`	`@0 Calcium @2 NC @2 FR @5 78`
C03	`10`	`X`	`ENG`	`@0 Calcium @2 NC @2 FR @5 78`
C03	`10`	`X`	`SPA`	`@0 Calcio @2 NC @2 FR @5 78`
C03	`11`	`X`	`FRE`	`@0 Elément minéral @5 79`
C03	`11`	`X`	`ENG`	`@0 Inorganic element @5 79`
C03	`11`	`X`	`SPA`	`@0 Elemento inorgánico @5 79`
C07	`01`	`X`	`FRE`	`@0 Système ostéoarticulaire pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Diseases of the osteoarticular system @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema osteoarticular patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Traumatisme @5 38`
C07	`02`	`X`	`ENG`	`@0 Trauma @5 38`
C07	`02`	`X`	`SPA`	`@0 Traumatismo @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 42`
C07	`06`	`X`	`ENG`	`@0 Central nervous system disease @5 42`
C07	`06`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 42`
C07	`07`	`X`	`FRE`	`@0 Trouble équilibre hydroélectrolytique @5 43`
C07	`07`	`X`	`ENG`	`@0 Hydroelectrolytic balance disorder @5 43`
C07	`07`	`X`	`SPA`	`@0 Trastorno equilibrio hidroelectrolítico @5 43`
C07	`08`	`X`	`FRE`	`@0 Trouble métabolisme @5 44`
C07	`08`	`X`	`ENG`	`@0 Metabolic disorder @5 44`
C07	`08`	`X`	`SPA`	`@0 Trastorno metabolismo @5 44`
N21				`@1 261`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 06-0393852 INIST
ET :	Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease : A randomized controlled trial
AU :	SATO (Yoshihiro); IWAMOTO (Jun); KANOKO (Tomohiro); SATOH (Kei)
AF :	Department of Neurology, Mitate Hospital/Tagawa/Japon (1 aut.); Department of Sports Medicine, Keio University School of Medicine/Tokyo/Japon (2 aut.); Department of Rehabilitation Medicine, Institute of Brain Science, Hirosaki University School of Medicine/Hirosaki/Japon (3 aut.); Department of Vascular Biology, Institute of Brain Science, Hirosaki University School of Medicine/Hirosaki/Japon (4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2006; Vol. 21; No. 7; Pp. 924-929; Bibl. 23 ref.
LA :	Anglais
EA :	Incidence of a fracture, particularly in the hip joint, is high in elderly women with Parkinson's disease (PD), and this is due to the immobilization-induced bone resorption and vitamin D deficiency with reduced bone mineral density (BMD). The objective of this study was to address the possibility that treatment with alendronate and vitamin D2 may reduce the incidence of hip fractures in elderly women with PD. PD patients were randomly assigned to daily treatment with 5 mg alendronate (n = 144) or a placebo combined with 1,000 IU of vitamin D2 (n = 144) and followed for 2 years. Incidence of hip fractures in the two patient groups during the 2-year follow-up period was studied. At baseline, both groups of patients had low BMD with high levels of serum-ionized calcium and urinary deoxypyridinoline (D-Pyr). Hip fractures occurred in 14 patients in the placebo group and 4 in the alendronate group. The relative risk for hip fractures in the alendronate group as compared with the placebo group was 0.29 (95% CI, 0.10-0.85). The number of hip fracture per 1,000 patient-years was 14 and 49 for the alendronate and placebo groups, respectively. In the alendronate group, serum calcium and urinary D-Pyr levels decreased significantly during the follow-up period, while the levels in the placebo group were increased. BMD increased by 3.1% in the alendronate group and decreased by 2.8% in the placebo group (P < 0.01). Treatment with alendronate and vitamin D2 increases BMD in elderly women with PD and leads to the prevention of hip fractures.
CC :	002B17; 002B17G; 002B17A03
FD :	Système nerveux pathologie; Fracture; Parkinson maladie; Hypercalcémie; Acide alendronique; Ergocalciférol; Prévention; Hanche; Vitamine D; Calcium; Elément minéral
FG :	Système ostéoarticulaire pathologie; Traumatisme; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Trouble équilibre hydroélectrolytique; Trouble métabolisme
ED :	Nervous system diseases; Fracture; Parkinson disease; Hypercalcemia; Alendronic acid; Ergocalciferol; Prevention; Hip; Vitamin D; Calcium; Inorganic element
EG :	Diseases of the osteoarticular system; Trauma; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Hydroelectrolytic balance disorder; Metabolic disorder
SD :	Sistema nervioso patología; Fractura; Parkinson enfermedad; Hipercalcemia; Acido alendrónico; Ergocalciferol; Prevención; Cadera; Vitamina D; Calcio; Elemento inorgánico
LO :	INIST-20953.354000133412770070
ID :	06-0393852

Links to Exploration step

Pascal:06-0393852

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease : A randomized controlled trial</title>
<author><name sortKey="Sato, Yoshihiro" sort="Sato, Yoshihiro" uniqKey="Sato Y" first="Yoshihiro" last="Sato">Yoshihiro Sato</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Mitate Hospital</s1>
<s2>Tagawa</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Iwamoto, Jun" sort="Iwamoto, Jun" uniqKey="Iwamoto J" first="Jun" last="Iwamoto">Jun Iwamoto</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Sports Medicine, Keio University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kanoko, Tomohiro" sort="Kanoko, Tomohiro" uniqKey="Kanoko T" first="Tomohiro" last="Kanoko">Tomohiro Kanoko</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Rehabilitation Medicine, Institute of Brain Science, Hirosaki University School of Medicine</s1>
<s2>Hirosaki</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Satoh, Kei" sort="Satoh, Kei" uniqKey="Satoh K" first="Kei" last="Satoh">Kei Satoh</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Vascular Biology, Institute of Brain Science, Hirosaki University School of Medicine</s1>
<s2>Hirosaki</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0393852</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0393852 INIST</idno>
<idno type="RBID">Pascal:06-0393852</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A92</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease : A randomized controlled trial</title>
<author><name sortKey="Sato, Yoshihiro" sort="Sato, Yoshihiro" uniqKey="Sato Y" first="Yoshihiro" last="Sato">Yoshihiro Sato</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Mitate Hospital</s1>
<s2>Tagawa</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Iwamoto, Jun" sort="Iwamoto, Jun" uniqKey="Iwamoto J" first="Jun" last="Iwamoto">Jun Iwamoto</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Sports Medicine, Keio University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kanoko, Tomohiro" sort="Kanoko, Tomohiro" uniqKey="Kanoko T" first="Tomohiro" last="Kanoko">Tomohiro Kanoko</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Rehabilitation Medicine, Institute of Brain Science, Hirosaki University School of Medicine</s1>
<s2>Hirosaki</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Satoh, Kei" sort="Satoh, Kei" uniqKey="Satoh K" first="Kei" last="Satoh">Kei Satoh</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Vascular Biology, Institute of Brain Science, Hirosaki University School of Medicine</s1>
<s2>Hirosaki</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alendronic acid</term>
<term>Calcium</term>
<term>Ergocalciferol</term>
<term>Fracture</term>
<term>Hip</term>
<term>Hypercalcemia</term>
<term>Inorganic element</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Prevention</term>
<term>Vitamin D</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Fracture</term>
<term>Parkinson maladie</term>
<term>Hypercalcémie</term>
<term>Acide alendronique</term>
<term>Ergocalciférol</term>
<term>Prévention</term>
<term>Hanche</term>
<term>Vitamine D</term>
<term>Calcium</term>
<term>Elément minéral</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Incidence of a fracture, particularly in the hip joint, is high in elderly women with Parkinson's disease (PD), and this is due to the immobilization-induced bone resorption and vitamin D deficiency with reduced bone mineral density (BMD). The objective of this study was to address the possibility that treatment with alendronate and vitamin D2 may reduce the incidence of hip fractures in elderly women with PD. PD patients were randomly assigned to daily treatment with 5 mg alendronate (n = 144) or a placebo combined with 1,000 IU of vitamin D2 (n = 144) and followed for 2 years. Incidence of hip fractures in the two patient groups during the 2-year follow-up period was studied. At baseline, both groups of patients had low BMD with high levels of serum-ionized calcium and urinary deoxypyridinoline (D-Pyr). Hip fractures occurred in 14 patients in the placebo group and 4 in the alendronate group. The relative risk for hip fractures in the alendronate group as compared with the placebo group was 0.29 (95% CI, 0.10-0.85). The number of hip fracture per 1,000 patient-years was 14 and 49 for the alendronate and placebo groups, respectively. In the alendronate group, serum calcium and urinary D-Pyr levels decreased significantly during the follow-up period, while the levels in the placebo group were increased. BMD increased by 3.1% in the alendronate group and decreased by 2.8% in the placebo group (P < 0.01). Treatment with alendronate and vitamin D2 increases BMD in elderly women with PD and leads to the prevention of hip fractures.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>21</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease : A randomized controlled trial</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SATO (Yoshihiro)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>IWAMOTO (Jun)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KANOKO (Tomohiro)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SATOH (Kei)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Mitate Hospital</s1>
<s2>Tagawa</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Sports Medicine, Keio University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Rehabilitation Medicine, Institute of Brain Science, Hirosaki University School of Medicine</s1>
<s2>Hirosaki</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Vascular Biology, Institute of Brain Science, Hirosaki University School of Medicine</s1>
<s2>Hirosaki</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>924-929</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000133412770070</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>23 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0393852</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Incidence of a fracture, particularly in the hip joint, is high in elderly women with Parkinson's disease (PD), and this is due to the immobilization-induced bone resorption and vitamin D deficiency with reduced bone mineral density (BMD). The objective of this study was to address the possibility that treatment with alendronate and vitamin D2 may reduce the incidence of hip fractures in elderly women with PD. PD patients were randomly assigned to daily treatment with 5 mg alendronate (n = 144) or a placebo combined with 1,000 IU of vitamin D2 (n = 144) and followed for 2 years. Incidence of hip fractures in the two patient groups during the 2-year follow-up period was studied. At baseline, both groups of patients had low BMD with high levels of serum-ionized calcium and urinary deoxypyridinoline (D-Pyr). Hip fractures occurred in 14 patients in the placebo group and 4 in the alendronate group. The relative risk for hip fractures in the alendronate group as compared with the placebo group was 0.29 (95% CI, 0.10-0.85). The number of hip fracture per 1,000 patient-years was 14 and 49 for the alendronate and placebo groups, respectively. In the alendronate group, serum calcium and urinary D-Pyr levels decreased significantly during the follow-up period, while the levels in the placebo group were increased. BMD increased by 3.1% in the alendronate group and decreased by 2.8% in the placebo group (P < 0.01). Treatment with alendronate and vitamin D2 increases BMD in elderly women with PD and leads to the prevention of hip fractures.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17A03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Fracture</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Fracture</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Fractura</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Hypercalcémie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Hypercalcemia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Hipercalcemia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Acide alendronique</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Alendronic acid</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Acido alendrónico</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Ergocalciférol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Ergocalciferol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Ergocalciferol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Prévention</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Prevention</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Prevención</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Hanche</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Hip</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Cadera</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Vitamine D</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Vitamin D</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Vitamina D</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Calcium</s0>
<s2>NC</s2>
<s2>FR</s2>
<s5>78</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Calcium</s0>
<s2>NC</s2>
<s2>FR</s2>
<s5>78</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Calcio</s0>
<s2>NC</s2>
<s2>FR</s2>
<s5>78</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Elément minéral</s0>
<s5>79</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Inorganic element</s0>
<s5>79</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Elemento inorgánico</s0>
<s5>79</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système ostéoarticulaire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Diseases of the osteoarticular system</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema osteoarticular patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Traumatisme</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Trauma</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Traumatismo</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Trouble équilibre hydroélectrolytique</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Hydroelectrolytic balance disorder</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Trastorno equilibrio hidroelectrolítico</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Trouble métabolisme</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Metabolic disorder</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Trastorno metabolismo</s0>
<s5>44</s5>
</fC07>
<fN21><s1>261</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 06-0393852 INIST</NO>
<ET>Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease : A randomized controlled trial</ET>
<AU>SATO (Yoshihiro); IWAMOTO (Jun); KANOKO (Tomohiro); SATOH (Kei)</AU>
<AF>Department of Neurology, Mitate Hospital/Tagawa/Japon (1 aut.); Department of Sports Medicine, Keio University School of Medicine/Tokyo/Japon (2 aut.); Department of Rehabilitation Medicine, Institute of Brain Science, Hirosaki University School of Medicine/Hirosaki/Japon (3 aut.); Department of Vascular Biology, Institute of Brain Science, Hirosaki University School of Medicine/Hirosaki/Japon (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2006; Vol. 21; No. 7; Pp. 924-929; Bibl. 23 ref.</SO>
<LA>Anglais</LA>
<EA>Incidence of a fracture, particularly in the hip joint, is high in elderly women with Parkinson's disease (PD), and this is due to the immobilization-induced bone resorption and vitamin D deficiency with reduced bone mineral density (BMD). The objective of this study was to address the possibility that treatment with alendronate and vitamin D2 may reduce the incidence of hip fractures in elderly women with PD. PD patients were randomly assigned to daily treatment with 5 mg alendronate (n = 144) or a placebo combined with 1,000 IU of vitamin D2 (n = 144) and followed for 2 years. Incidence of hip fractures in the two patient groups during the 2-year follow-up period was studied. At baseline, both groups of patients had low BMD with high levels of serum-ionized calcium and urinary deoxypyridinoline (D-Pyr). Hip fractures occurred in 14 patients in the placebo group and 4 in the alendronate group. The relative risk for hip fractures in the alendronate group as compared with the placebo group was 0.29 (95% CI, 0.10-0.85). The number of hip fracture per 1,000 patient-years was 14 and 49 for the alendronate and placebo groups, respectively. In the alendronate group, serum calcium and urinary D-Pyr levels decreased significantly during the follow-up period, while the levels in the placebo group were increased. BMD increased by 3.1% in the alendronate group and decreased by 2.8% in the placebo group (P < 0.01). Treatment with alendronate and vitamin D2 increases BMD in elderly women with PD and leads to the prevention of hip fractures.</EA>
<CC>002B17; 002B17G; 002B17A03</CC>
<FD>Système nerveux pathologie; Fracture; Parkinson maladie; Hypercalcémie; Acide alendronique; Ergocalciférol; Prévention; Hanche; Vitamine D; Calcium; Elément minéral</FD>
<FG>Système ostéoarticulaire pathologie; Traumatisme; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Trouble équilibre hydroélectrolytique; Trouble métabolisme</FG>
<ED>Nervous system diseases; Fracture; Parkinson disease; Hypercalcemia; Alendronic acid; Ergocalciferol; Prevention; Hip; Vitamin D; Calcium; Inorganic element</ED>
<EG>Diseases of the osteoarticular system; Trauma; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Hydroelectrolytic balance disorder; Metabolic disorder</EG>
<SD>Sistema nervioso patología; Fractura; Parkinson enfermedad; Hipercalcemia; Acido alendrónico; Ergocalciferol; Prevención; Cadera; Vitamina D; Calcio; Elemento inorgánico</SD>
<LO>INIST-20953.354000133412770070</LO>
<ID>06-0393852</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A92 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001A92 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:06-0393852
   |texte=   Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease : A randomized controlled trial
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease : A randomized controlled trial

Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease : A randomized controlled trial

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri